Published in Clin Cancer Res on January 06, 2012
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS One (2015) 1.51
Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. J Natl Cancer Inst (2014) 1.48
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res (2012) 1.00
The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. Oncotarget (2015) 0.98
Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol (2014) 0.95
Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas. Cancer Res (2015) 0.92
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res (2014) 0.90
Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics (2014) 0.89
Selecting cases for whom additional tests can improve prognostication. AMIA Annu Symp Proc (2012) 0.89
Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma. PLoS One (2013) 0.87
Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer (2015) 0.86
HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma. PLoS One (2012) 0.83
CLT1 targets bladder cancer through integrin α5β1 and CLIC3. Mol Cancer Res (2012) 0.82
Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2. J Korean Med Sci (2014) 0.82
Bladder cancer: a simple model becomes complex. Curr Genomics (2012) 0.81
Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer (2014) 0.81
Ruguo key genes and tumor driving factors identification of bladder cancer based on the RNA-seq profile. Onco Targets Ther (2016) 0.81
Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients. Chin J Cancer (2013) 0.80
Nomogram based on systemic inflammatory response markers predicting the survival of patients with resectable gastric cancer after D2 gastrectomy. Oncotarget (2016) 0.80
Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma. Am J Cancer Res (2016) 0.79
A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting. World J Urol (2012) 0.79
Competing risks data analysis with high-dimensional covariates: an application in bladder cancer. Genomics Proteomics Bioinformatics (2015) 0.79
E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer. Mol Cancer Res (2015) 0.79
Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics (2016) 0.78
An essential role for decorin in bladder cancer invasiveness. EMBO Mol Med (2013) 0.78
One-step extrapolation of the prediction performance of a gene signature derived from a small study. BMJ Open (2015) 0.78
An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer. BMC Urol (2015) 0.78
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep (2016) 0.77
High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. BMC Cancer (2014) 0.76
Urothelial cancer gene regulatory networks inferred from large-scale RNAseq, Bead and Oligo gene expression data. BMC Syst Biol (2015) 0.76
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene (2016) 0.75
Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation. Oncotarget (2016) 0.75
Predicting the Survival Time for Bladder Cancer Using an Additive Hazards Model in Microarray Data. Iran J Public Health (2016) 0.75
Gene expression profiling in bladder cancer identifies potential therapeutic targets. Int J Oncol (2017) 0.75
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer (2016) 0.75
RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis (2017) 0.75
Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget (2016) 0.75
Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis (2015) 0.75
Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy. World J Surg Oncol (2017) 0.75
FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma. Sci Rep (2016) 0.75
Tobacco-specific carcinogens induce hypermethylation, DNA adducts and DNA damage in Bladder Cancer. Cancer Prev Res (Phila) (2017) 0.75
Beat-ID: Towards a computationally low-cost single heartbeat biometric identity check system based on electrocardiogram wave morphology. PLoS One (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
ROCR: visualizing classifier performance in R. Bioinformatics (2005) 19.60
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics (2006) 10.83
A global test for groups of genes: testing association with a clinical outcome. Bioinformatics (2004) 10.82
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
Bladder cancer. Lancet (2009) 4.43
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med (2011) 4.34
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet (2002) 3.82
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol (2001) 2.56
Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer (2010) 2.41
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
Defining optimal therapy for muscle invasive bladder cancer. J Urol (2007) 2.30
Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res (2005) 2.29
Genomics and the continuum of cancer care. N Engl J Med (2011) 2.26
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res (2010) 1.99
Cross-validated Cox regression on microarray gene expression data. Stat Med (2006) 1.90
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol (2006) 1.82
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol (2009) 1.62
Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med (2010) 1.55
Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol (2009) 1.32
Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol (2010) 1.31
Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int (2005) 1.20
Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am (2003) 1.14
A gene expression signature associated with survival in metastatic melanoma. J Transl Med (2006) 1.13
Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clin Cancer Res (2010) 1.04
Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results. Urol Oncol (2006) 0.87
QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids Res (2007) 10.08
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008) 5.64
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg (2009) 3.76
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell (2012) 3.39
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol (2010) 3.02
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol (2010) 2.80
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Results of chest wall resection and reconstruction with and without rigid prosthesis. Ann Thorac Surg (2006) 2.77
DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol (2011) 2.62
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Synergy and discounting of cooperation in social dilemmas. J Theor Biol (2005) 2.49
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Stochastic tunnels in evolutionary dynamics. Genetics (2004) 2.42
Evolution of resistance during clonal expansion. Genetics (2006) 2.36
Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg (2008) 2.33
Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol (2010) 2.32
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res (2005) 2.29
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol (2010) 2.27
Efficient experimental design and analysis strategies for the detection of differential expression using RNA-Sequencing. BMC Genomics (2012) 2.19
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18
A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol (2010) 2.15
The chromosome 6p22 haplotype associated with dyslexia reduces the expression of KIAA0319, a novel gene involved in neuronal migration. Hum Mol Genet (2006) 2.14
Video-assisted thoracoscopic surgery (VATS) lobectomy: catastrophic intraoperative complications. J Thorac Cardiovasc Surg (2011) 2.11
Functional classification analysis of somatically mutated genes in human breast and colorectal cancers. Genomics (2008) 2.11
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg (2006) 2.03
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in speech and language disorders. Am J Hum Genet (2007) 2.01
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res (2014) 1.96
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res (2005) 1.85
High resolution mapping of expression QTLs in heterogeneous stock mice in multiple tissues. Genome Res (2009) 1.83
The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol (2011) 1.81
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81
Pervasive haplotypic variation in the spliceo-transcriptome of the human major histocompatibility complex. Genome Res (2011) 1.80
Successful therapy must eradicate cancer stem cells. Stem Cells (2006) 1.78
Evolutionary dynamics of invasion and escape. J Theor Biol (2004) 1.78
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res (2007) 1.75
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer (2006) 1.75
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol (2011) 1.69
The linear process of somatic evolution. Proc Natl Acad Sci U S A (2003) 1.66
Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res (2004) 1.66
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer (2011) 1.62
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer (2008) 1.62
Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A (2004) 1.61
Lung adenocarcinoma subtypes based on expression of human airway basal cell genes. Eur Respir J (2013) 1.59
DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat Struct Mol Biol (2011) 1.56
Foxp2 regulates gene networks implicated in neurite outgrowth in the developing brain. PLoS Genet (2011) 1.56
Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol (2011) 1.55
Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer (2006) 1.53
Urachal carcinoma: contemporary surgical outcomes. J Urol (2007) 1.53
FLOWERING LOCUS C (FLC) regulates development pathways throughout the life cycle of Arabidopsis. Proc Natl Acad Sci U S A (2011) 1.53
The evolution of two mutations during clonal expansion. Genetics (2007) 1.52
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet (2013) 1.50
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol (2004) 1.50
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol (2010) 1.48
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol (2010) 1.47
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials. Innovations (Phila) (2007) 1.46
Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer. J Urol (2013) 1.44
Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol (2009) 1.43
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol (2007) 1.41
Evolutionary theory of cancer. Ann N Y Acad Sci (2009) 1.41
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol (2002) 1.41
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood (2011) 1.40
Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. BJU Int (2011) 1.40
Trans chromosomal methylation in Arabidopsis hybrids. Proc Natl Acad Sci U S A (2012) 1.40
A genome-wide survey of imprinted genes in rice seeds reveals imprinting primarily occurs in the endosperm. PLoS Genet (2011) 1.39
Comparison of perioperative outcomes for epidural versus intravenous patient-controlled analgesia after radical cystectomy. Reg Anesth Pain Med (2015) 1.39
Evolutionary dynamics of escape from biomedical intervention. Proc Biol Sci (2003) 1.38
Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol (2010) 1.38
The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int (2009) 1.38
(A)symmetric stem cell replication and cancer. PLoS Comput Biol (2007) 1.36
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol (2010) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One (2011) 1.32